登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：600085 公司简称：同仁堂 第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1、公司简介 ■ 2、报告期公司主要业务简介 2024年是实现"十四五"目标任务的关键一年，党和政府着力推动中医药振兴发展，党的二十届三中全会 提出"完善中医药传承创新发展机制"，适合我国中医药发展的标准体系框架已基本建立。2024年4月， 北京市医疗保障局等九部门印发《北京市支持创新医药高质量发展若干措施（2024年）》，推进创新 链、产业链和政策链深度融合，优化要素资源配置，加速医药健康产业创新，以更好满足人民群众防病 治病需求。2024年7月，国家中医药管理局印发《中医药标准化行动计划（2024一2026年）》，坚持统 筹协调、需求导向、质量优先、应用为本的原则，扬优势、补短板、激 ...

投资要点 毛利率短期承压，中期有望持续修复。2024 年心脑血管产品毛利率同比下降8.31pct，仅为49.31%，在 过去5 年中首次向下跌破50%，对短期利润增长带来压力，我们认为主要系原材料天然牛黄较同期涨价 所致。根据中药材天地网数据显示，2024 年12 月底天然牛黄市场价格为170 万元/公斤，相比2023 年初 的57万元/公斤提升了198.25%。我们预计公司毛利率压力有望在2025 年陆续改善，主要系(1)进口牛黄 加持：2024 年7 月1 日，国家药监局综合司、海关总署办公厅就《关于允许进口牛黄试点用于中成药生 产有关事项的公告（征求意见稿）》，未来随着海外相对低价牛黄的进入，公司成本压力有望逐步缓 解。(2)产品有调整价格的可能性：据同仁堂国药2024 年年报显示，2024 年下半年上调了在香港市场销 售的安宫牛黄丸价格，在原材料价格压力导致同仁堂心脑血管产品毛利率持续下降并创新低的情况下， 不排除后续调整大陆地区安宫牛黄丸价格的可能性。 分红提升彰显信心。公司发布《2024 年度利润分配预案公告》，2024 年度公司现金分红(包括中期已分 配的现金红利)总额13.71 亿元，占本年度 ...

Group 1 - Fudan University Zhongshan Hospital has developed a bile duct cancer precision testing kit that has received approval from the Shanghai Municipal Drug Administration, achieving an 86% increase in overall detection rate and reducing average testing time from 17.6 days to 5 days [1] - Jianyou Co., Ltd. announced that its liraglutide injection has received FDA approval, which may enhance its competitiveness and brand influence in the international market [2] - Jiangsu Lifeng Biotechnology was fined a total of 37.73 million yuan for falsifying registration documents for medical devices, highlighting the regulatory body's zero-tolerance policy towards fraud [3] Group 2 - Tongrentang reported a 4.12% increase in total operating revenue for 2024, reaching 18.597 billion yuan, but its net profit decreased by 8.54% to 1.526 billion yuan, attributed to rising raw material costs and imbalances in marketing and R&D investments [4]

Group 1 - The independent director, Wang Guihua, has been serving since June 25, 2021, and has not exceeded six years in this role, maintaining independence and compliance with regulations [1][2] - During the reporting period, the independent director attended all meetings and actively participated in discussions, ensuring objective and independent opinions were provided [2][3] - The independent director emphasized the importance of communication with the board and management to safeguard the interests of minority shareholders [1][4] Group 2 - The independent director participated in various committees, including the Nomination Committee and the Remuneration and Assessment Committee, attending all scheduled meetings and voting in favor of all proposals [2][3] - Key issues addressed included related party transactions and commitments from controlling shareholders to avoid competition, with independent opinions provided to ensure compliance with legal standards [4][7] - The independent director maintained communication with external auditors and internal audit departments to ensure accurate financial reporting and effective internal controls [5][9] Group 3 - The company has implemented a robust process for selecting and appointing auditors, with the independent director overseeing compliance with relevant laws and regulations [5][10] - The independent director has been actively involved in the evaluation of the company's internal control systems and has encouraged ongoing improvements [9][11] - The independent director has also engaged with minority shareholders through various forums, enhancing transparency and trust [6][12] Group 4 - The independent director has committed to continuing to uphold independence and diligence in fulfilling responsibilities, focusing on governance and operational decisions [12] - The independent director aims to provide valuable insights and recommendations to support the company's sustainable growth and protect shareholder interests [12]

Core Viewpoint - Beijing Tong Ren Tang Co., Ltd. plans to distribute a cash dividend of 0.50 RMB per share (including tax), based on the total share capital registered on the dividend distribution date [1] Profit Distribution Plan - The company intends to distribute a cash dividend of 5.00 RMB for every 10 shares held, amounting to a total cash dividend of approximately 44.93% based on the total share capital of 1,371,470,262 shares as of December 31, 2024 [1][2] - The total undistributed profits as of December 31, 2024, are reported at 8,386,175,950.07 RMB for the consolidated financial statements and 3,804,841,930.31 RMB for the parent company [1][2] Historical Cash Dividends - The total cash dividends for the last three fiscal years are as follows: - Current year: 1,371,470,262.00 RMB - Previous year: 685,735,131.00 RMB - Year before last: 438,870,483.84 RMB [2] - The cumulative cash dividends over the last three years amount to 2,496,075,876.84 RMB [2] Decision-Making Process - The company's board of directors approved the profit distribution plan during the seventh meeting of the tenth board on April 2, 2025, confirming it aligns with the company's profit distribution policy [3] - The supervisory board also agreed with the profit distribution plan, emphasizing its consideration of the company's profitability, operational needs, and reasonable returns for shareholders [3]

Meeting Overview - The sixth meeting of the 10th Supervisory Board of Beijing Tongrentang Co., Ltd. was held on April 2, 2025, combining in-person and telecommunication methods [1] - All five supervisors attended the meeting, and it was presided over by Chairman Wang Xingwu [1] Resolutions Passed - The 2024 Financial Settlement Report was approved with a unanimous vote of 5 in favor [2] - The 2024 Profit Distribution Plan was approved, considering the company's profitability, operational needs, and reasonable returns for shareholders, and will be submitted to the shareholders' meeting for review [1][2] - The 2024 Supervisory Board Work Report was approved with a unanimous vote of 5 in favor [2] - The 2024 Annual Report and its summary were approved, confirming compliance with legal and regulatory requirements, and reflecting the company's actual operational situation accurately [2] - The 2024 Internal Control Evaluation Report was approved with a unanimous vote of 5 in favor [2] - The 2024 Environmental, Social, and Governance (ESG) Report was approved with a unanimous vote of 5 in favor [2] - The proposal regarding the 2024 Supervisory Board remuneration was approved with 3 votes in favor and 2 abstentions [2] Additional Notes - The first, second, third, fourth, and seventh resolutions will be submitted to the 2024 Annual Shareholders' Meeting for further review [2]

北京同仁堂股份有限公司 内部控制审计报告 众环审字(2025)0203634号 内部控制审计报告 众环审字(2025)0203634 号 北京同仁堂股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了北 京同仁堂股份有限公司（以下简称"同仁堂公司"）2024 年 12 月 31 日的财务报告内部控制 的有效性。 一、同仁堂公司对内部控制的责任 中审众环会计师事务所（特殊普通合伙） 中国注册会计师： 郝国敏 中国注册会计师： 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制，并评价其有效性是同仁堂公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报 ...

北京同仁堂股份有限公司独立董事 2024 年度述职报告 （杨庆英） 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》、 中国证券监督管理委员会《上市公司独立董事管理办法》等法律、法规、规范性文件 和《北京同仁堂股份有限公司章程》（以下简称《公司章程》）、《北京同仁堂股份有限 公司独立董事管理办法》（以下简称《独立董事管理办法》）等规定，本人作为北京同 仁堂股份有限公司（以下简称公司）的独立董事，现就 2024 年度（以下简称报告期） 履行独立董事职责情况作如下报告： 一、 基本情况 本人简历情况详见公司 2024 年年度报告。 本人自 2023 年 1 月 9 日担任公司独立董事，截止本述职报告披露日，本人连续担 任公司独立董事职务未超过六年，兼职境内上市公司独立董事的数量未超过 3 家。作 为公司的独立董事，本人不存在影响可能影响独立性的情况，本人已向董事会递交了 2024 年度独立性自查报告，董事会对本人的独立性情况进行了评估并出具专项意见。 二、 报告期履职概况 (一) 出席会议情况及发表意见情况 在报告期间，本人严格遵循相关法律法规以及《公司章程》《独立董事管理办法》 的规 ...

北京同仁堂股份有限公司独立董事 2024 年度述职报告 （乔延江） 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》、 中国证券监督管理委员会《上市公司独立董事管理办法》等法律、法规、规范性文件 和《北京同仁堂股份有限公司章程》（以下简称《公司章程》）、《北京同仁堂股份有限 公司独立董事管理办法》（以下简称《独立董事管理办法》）等规定，本人作为北京同 仁堂股份有限公司（以下简称公司）的独立董事，现就 2024 年度（以下简称报告期） 履行独立董事职责情况作如下报告： 一、 基本情况 本人简历情况详见公司 2024 年年度报告。 本人自 2021 年 6 月 25 日担任公司独立董事，截止本述职报告披露日，本人连续 担任公司独立董事职务未超过六年，兼职境内上市公司独立董事的数量未超过 3 家。 作为公司的独立董事，本人不存在影响可能影响独立性的情况，本人已向董事会递交 了 2024 年度独立性自查报告，董事会对本人的独立性情况进行了评估并出具专项意见。 二、 报告期履职概况 (一) 出席会议情况及发表意见情况 | 独立 | 会议名称 | 出席情况（次） | | | 表决情况 | | ...